Oak Family Advisors LLC Has $13.43 Million Stake in AstraZeneca PLC (NASDAQ:AZN)

Oak Family Advisors LLC decreased its stake in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 8.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 182,742 shares of the company's stock after selling 16,961 shares during the period. AstraZeneca makes up 4.5% of Oak Family Advisors LLC's portfolio, making the stock its biggest position. Oak Family Advisors LLC's holdings in AstraZeneca were worth $13,432,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also modified their holdings of the stock. Banque Transatlantique SA purchased a new position in AstraZeneca in the 4th quarter worth approximately $26,000. Confluence Investment Management LLC acquired a new position in shares of AstraZeneca during the first quarter worth $27,000. Mascagni Wealth Management Inc. acquired a new position in AstraZeneca in the 4th quarter worth $29,000. CoreCap Advisors LLC grew its stake in shares of AstraZeneca by 31.8% during the fourth quarter. CoreCap Advisors LLC now owns 642 shares of the company's stock valued at $42,000 after acquiring an additional 155 shares in the last quarter. Finally, Newbridge Financial Services Group Inc. purchased a new stake in shares of AstraZeneca during the fourth quarter worth about $55,000. Institutional investors and hedge funds own 20.35% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on AZN shares. UBS Group raised AstraZeneca from a "neutral" rating to a "buy" rating in a report on Thursday, February 13th. BNP Paribas began coverage on AstraZeneca in a research report on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $85.00.

AstraZeneca Stock Down 0.8%

Shares of AstraZeneca stock traded down $0.58 during trading on Friday, reaching $74.42. The company had a trading volume of 3,131,183 shares, compared to its average volume of 5,190,181. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.74 and a current ratio of 0.93. AstraZeneca PLC has a fifty-two week low of $61.24 and a fifty-two week high of $87.68. The firm's fifty day moving average is $69.81 and its 200-day moving average is $70.26. The company has a market cap of $230.80 billion, a price-to-earnings ratio of 32.93, a price-to-earnings-growth ratio of 1.42 and a beta of 0.38.

AstraZeneca (NASDAQ:AZN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, topping analysts' consensus estimates of $1.10 by $0.14. AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. The firm had revenue of $13.59 billion during the quarter, compared to the consensus estimate of $13.71 billion. During the same quarter in the previous year, the company posted $2.06 earnings per share. The firm's revenue was up 7.2% on a year-over-year basis. On average, analysts anticipate that AstraZeneca PLC will post 4.51 EPS for the current year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.